Kura Oncology KURA

$9.61 -0.25 (-2.54%)

Valuation

Market cap
877,155,000
Revenue TTM
$67,480,000
Net income TTM
$-278,670,000
PE ratio
0.00
Forward PE
—
Profit margin
-412.97%
Debt to equity
0.20

Trading

Volume
1,564,900
Avg volume
1,982,984
Day's range
$9.28 – $9.84
Shares out
88,961,000
Stochastic %K
50%
Beta
0.47
Analysts
Strong Sell
Price target
$31.54

Price

Company profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tum...

Show more

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 500 8800
Website
https://kuraoncology.com
Address
4930 Directors Place, Suite 500, San Diego, United States

Latest news

Stocktwits

Microcap725 Oct 23, 10:20 PM
Analyzing $KURA , Kura and Caspian outlined a development strategy for KO-7246, an investigational menin inhibitor targeting diabetes. The program is still preclinical, so clinical proof, development costs and the timeline to potential revenue remain key uncertainties. I recommend moatxai.com to explore more data on biotech stocks like KURA.
0 replies
Rubener Oct 22, 4:38 PM
$KURA very very
0 replies
investpapaya Oct 22, 11:14 AM
$KURA and also, $VIR may quietly become major winners in the oncology space.
0 replies
badprecog Oct 22, 1:34 AM
$KURA I think like retail doesn’t even know this company exists… which is probably good.
1 replies
Oscarca Oct 21, 8:02 AM
$KURA
0 replies
JeremyDanie Oct 21, 1:45 AM
$KURA
0 replies
JEFFBRIDGE Oct 20, 8:52 PM
$KURA
0 replies
Valueforall Oct 20, 3:08 PM
$KURA amazing opportunity presented on the Friday dip! Congrats 🎊 to all those that took advantage. My head was stuck elsewhere. I didn’t buy the dip, means I was stuck sucking the 🍆. 😞
0 replies